Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

NCT05218603 · clinicaltrials.gov ↗

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Non-eligible for Autologous Stem Cell Transplantation (ASCT)

Interventions

DRUG: Bortezomib
DRUG: Daratumumab

Sponsor

PETHEMA Foundation

Collaborators

[object Object]
[object Object]